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Background: The purpose of the study is to compare the clinico-microbiological profile and treatment outcome
of in-house vs referred cases of post cataract surgery endophthalmitis in a tertiary eye care facility in South India.
Methods: The clinical records of 50 culture-positive cases each of in-house (group A) and referred (group B) post
cataract surgery endophthalmitis were analyzed. The management protocol was similar in both groups.
Results: The time to report to the institute was longer in group B (group B 13.63 [±11.67; 95% CI, 9.95–17.31] days;
group A 6.83 [±7.61; 95% CI, 4.57–9.09] days; P = 0.002). The average inflammatory scores in presentation were
comparable (group A 17.85 ± 5.83; group B 18.18 ± 7.35; P = 0.243). The final visual outcome was clinically superior
in group A (≥20/200-group A 60.42% and group B 44%, P = 0.11; ≤20/400-group A 37.5% and group B 52%, P = 0.62),
but statistically not significant. There were more gram-positive organisms in group A (62% vs 38%; P = 0.027) and
more gram-negative organisms in group B (52% vs 24%; P = 0.007). Gram-positive bacteria were mostly sensitive to
vancomycin (95.24% to 96.67%), but gram-negative bacteria were partly sensitive to ceftazidime (58.33% to 64%).
Conclusions: One could suspect gram-negative infection more often in the referred cases of endophthalmitis. While
vancomycin could continue to be the antibiotic of choice in gram-positive bacteria, specific antibiotic following due
sensitivity for gram-negative bacteria should replace the empiric use of ceftazidime.Background
Patients with post cataract surgery endophthalmitis
treated by us at a tertiary eye care facility in Hyderabad,
India, are a pool of “in-house” and “referred” cases for
further management. A decade and half ago, we reported
the microbiological profile of these pooled patients [1]
in which the gram-positive cocci accounted for less than* Correspondence: tpd@lvpei.org
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the Creative Commons license, and indicate if50% eyes and gram-negative bacilli were detected in
more than 25% eyes. This was contrary to the report of
the Endophthalmitis Vitrectomy Study (EVS) [2] results
published before our report and also is contrary to the
European Society of Cataract and Refractive Surgery
(ESCRS) [3] study results published after our report. In
view of these differences, we reexamined the microbio-
logical profile and antibiotic sensitivity between two dis-
tinct groups of patients, in-house and referred, managed
at this facility. We hypothesized that the in-house en-
dophthalmitis profile (both clinical and microbiological)
and outcome after treatment could be different.is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
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The clinical records of all culture-positive cases of
post cataract surgery endophthalmitis managed at our
institute between January 2010 and December 2014
were reviewed. There were 50 cases of in-house
(group A) endophthalmitis. These 50 cases were
matched with the first 50 consecutive culture-positive
referred cases in the same period (group B; beginning
December 2014 backwards and ending March 2010).
Two cluster endophthalmitis cases, one in-house (re-
ported earlier) [4] and one referred (reported by an-
other treating center) [5] were excluded from both
groups. Institutional review board approval (LEC 09-
15-110) was obtained for retrospective data collection
and analysis.
A detailed ocular history (cataract surgery, event to
onset of symptoms, time to presentation, and previous
treatment history in referred cases), the demography
(age, gender), laterality, systemic factors (diabetes and
immune status) were recorded. Management of all
these patients was as per the institutional protocol.
Briefly, this consisted of a comprehensive clinical exam-
ination (uncorrected and best corrected visual acuity,
slit lamp biomicroscopy, applanation/digital tonometry,
indirect ophthalmoscopy) and ultrasonography. The se-
verity of inflammation in presentation was measured in
all cases by our earlier published inflammatory score
[6]. Briefly, this consisted of slit lamp and indirect oph-
thalmoscopic features of the cornea, anterior chamber,
iris, and vitreous in a scale of 0 (no involvement) to 4
(gross involvement) and additional allowance given for
any opaque ocular tissues not allowing further examin-
ation. The treatment consisted of intraocular antibiotics
(vancomycin 1 mg in 0.1 ml normal saline; ceftazidime
2.25 mg in 0.1 ml normal saline) with either vitreous
biopsy or core vitrectomy. This was followed with top-
ical antibiotics (every 2 h), topical prednisolone acetate
1% (every 4 h) except in the eyes with significant cor-
neal infiltrate and cycloplegic (every 8 h). The use of
intravitreal corticosteroid (typically, dexamethasone
0.4 mg in 0.1 ml) and systemic antibiotics (typically,
oral ciprofloxacin 1500 mg/day in two divided doses, in
adult) were left to the discretion of the treating faculty.
The vitreous sample was plated on the same day for
culture. Microbiological work-up of undiluted vitreous
included microscopy (after vital dye staining), culture
(aerobic, anaerobic, and fungus), and antibiotic sensitiv-
ity (Kirby-Bauer disc diffusion). Unlike the current in-
stitutional standard, the polymerase chain reaction
(PCR) was not done routinely in this period. Any fur-
ther administration of intravitreal antibiotics with or
without corticosteroid was guided by the culture report
of the vitreous sample and the sensitivity of the cul-
tured microorganism.Statistical analysis
The ETDRS visual acuity was converted to logMAR
equivalent for statistical analysis. In each group, the
mean values of best corrected visual acuity (BCVA) at
baseline and at the last follow-up were compared by ana-
lysis of variance (ANOVA). The mean values detected in
the two groups at each time point were compared by t
test. The sensitivity profile of the microorganisms cultured
in the two groups was analyzed using the Fisher’s exact
test. Values of P < 0.05 were considered statistically signifi-
cant. The two in-house endophthalmitis patients were ex-
cluded from the analysis for final visual outcome and
inflammatory score because they received Descemet’s
stripping automated endothelial keratoplasty along with




There were 50 cases each in either group. Between the
two groups, there was no statistically significant difference
in the demographic profile and in the diabetes status.
There was a statistically significant difference between the
two groups in the time to report to the institute with en-
dophthalmitis (group A 6.83 [±7.61; 95% CI, 4.57–9.09]
days; group B 13.63 [±11.67; 95% CI, 9.95–17.31] days;
P = 0.002). There was no significant difference in aver-
age inflammatory score at presentation (group A 17.85
± 5.83; group B 18.18 ± 7.35; P = 0.243). These details
are shown in Table 1.
Visual outcome at last visit
The patients were followed up for a mean duration
of 7.14 (±6.41; range 1.03–44.3) months in group A
and 5.69 (± 5.27; range 1.0–28.73) months in group
B (P = 0.37). The improvement in visual acuity of
0.719 logMAR in group A (approximately 7 ETDRS
lines; 95% CI, 0.41–1.03, P < 0.001) and of 0.528
logMAR in group B (approximately 5 ETDRS lines;
95% CI, 0.32–0.74, P = 0.001) was statistically signifi-
cant, but not significantly different between the two
groups (P = 0.197). In general, the patients in group
A (in-house) had better visual recovery than group B
(referred) ≥20/200 in 60.42% (95% CI, 45.30–73.89)
instances in group A vs 44% (95% CI, 30.27–58.65)
instances in group B, and ≤20/400 in 37.5% (95% CI,
24.32-54.67) instances in group A and 52% (95% CI,
37.58–66.12) instances in group B. These were, how-
ever, only clinically significant (Table 1).
Microbiological profile
The microbiological profile is shown in Table 2. Group
A had more gram-positive bacteria (n = 31/50, 62%;
95% CI, 47.16–75.00 in group A vs n = 19/50, 38%; 95% CI,
Table 1 Baseline characteristics and final visual outcome
Group A. In-house (n = 50) Group B. Referred (n = 50) P value
Mean age (years) ± SD 58.13 ± 12.81 58.74 ± 13.29 0.41
Mean baseline BCVA logMAR (ETDRS equivalent) ± SD 1.99 (20/1954) ± 0.61 1.96 (20/1824) ± 0.45 0.48
Male: Female 29: 21 26: 24 0.55
Mean event to report time days (± SD, 95% CI) 6.83 (±7.61; 95% CI, 4.57 – 9.09) 13.63 (±11.67; 95% CI, 9.95 – 17.31) 0.002*
Number of diabetics 6 2 0.14
Inflammatory score (Mean ± SD) 17.85 ± 5.83 18.18 ± 7.35 0. 24
Final best corrected visual acuity
≥ 20/200 29 of 48 (60.42%; 95% CI, 45.30-73.89) 22 of 50 (44%; 95% CI, 30.27-58.65) 0.11
≤ 20/400 18 of 48 (37.5%; 95% CI, 24.32-54.67) 26 of 50 (52%; 95% CI, 37.58-66.12) 0.62
*Statistically significant
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gram-negative bacteria in group B (n = 12/50, 24%; 95% CI,
13.52–38.49 in group A vs n = 26/50, 52%; 95% CI,
37.58–66.12 in group B; P = 0.007). Statistically, there
was no significant difference in the number of fungal
infections (n = 4/50, 8%; 95% CI, 2.59–20.11 each, in
groups A and B; P = 1) or in the number of mixedTable 2 Microbiological spectrum
Isolate





















aStatistically significantinfections (n = 3/50, 6%; 95% CI, 1.56–17.54 in group A vs
n = 1/50, 2%; 95% CI, 0.1–12.01 in group B; P = 0.617).
Antibiotic-sensitivity profile
The sensitivity profile of the bacteria in the two groups
is shown in Figs. 1 and 2. More than 95% gram-positive
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Fig. 1 Antibiotic sensitivity profile of gram-positive isolates in groups A and B, showing percentage sensitivity with 95% CI
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tween 85% and 90% (90.32% gram-positive isolates in
group A, and in 85.71% in group B) were sensitive to
cefazolin. Only 58.33% of gram-negative isolates in
group A and 64% gram-negative isolates in group B were
sensitive to ceftazidime. The sensitivity of amikacin com-
pared to ceftazidime in both groups (group A: amikacin
80% vs ceftazidime 58.33% sensitive, P = 0.22; group B:
amikacin 73.06% vs ceftazidime 64% sensitive, P = 0.56)
was not statistically significant.
Ceftazidime resistance
In group A, 41.67% (5/12) gram-negative isolates were
resistant to ceftazidime and, of these five resistant cases,
only 40% (2/5) were sensitive to amikacin, but all were
sensitive to imipenem. The 3 amikacin resistant isolates
in group A belonged to Pseudomonas species. In groupFig. 2 Antibiotic sensitivity profile of gram-negative isolates in groups A anB, 36% (9/25) gram-negative isolates were resistant to
ceftazidime, and of these, 77.78% (7/9) were sensitive to
amikacin (Table 3).Prior therapy
Five patients had received prior therapy before being re-
ferred to us (Table 4). This included four adults and one
child. All of them had received vitreous biopsy/core vi-
trectomy and repeated intravitreal antibiotics. The pre-
senting vision was between light perception (n = 3) to
ambulatory vision. Three of them grew Pseudomonas
aeroginosa. For the following further treatment, none of
the eyes infected with P. aeruginosa recovered vision.
Two of the five patients, one infected with Rhizobium
radiobacter and one infected with Candida pelliculosa
recovered to 6/36 and 6/15, respectively.d B, showing percentage sensitivity with 95% CI
Table 3 Antibiotic sensitivity profile of ceftazidime-resistant gram- negative isolates in groups A and B
S No. Endophthalmitis isolate Amikacin Imipenem Chloramphenicol Ciprofloxacin Gatifloxacin Moxifloxacin Ofloxacin Tobramycin
Group A
1 Eschericia coli I S S R I R R NT
2 Enterobacter cloacae S S S I S I S R
3 Enterobacter cloacae S S R I S I S R
4 Pseudomonas aeruginosa R S R R R R NT NT
5 Pseudomonas aeruginosa R S R R R R NT NT
Group B
1 Achromobacter xylosoxidans S NT S S S S S S
2 Eschericia coli S NT S S S S S S
3 Klebsiela pneumoniae S S R R R R R S
4 Pseudomonas aeruginosa R S R R R R R R
5 Pseudomonas species S NT S S S S S S
6 Pseudomonas stutzeri R NT S S S R S R
7 Pseudomonas stutzeri S R R R R R R S
8 Sphingomonas paucimobilis S NT S R S R S S
9 Stenotrphomonas maltophilia S NT S S S S S S
I intermediate sensitivity, NT not tested, S sensitive, R resistant
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Endophthalmitis, the most dreaded complication follow-
ing cataract surgery, has an incidence from 0.04% to
0.13% [7–11]. Gram-positive bacteria were the predom-
inant isolates in the EVS [2] and the ESCRS [3] studies.
We and others in India have reported different micro-
biological profile of infection where the gram-positive
cocci infection was relatively less, and gram-negative ba-
cilli infection was relatively more common [1, 12]. These
reports included both in-house and referred cases of






1 70 IOAB LP PPV + 2x IOAB
2 10 2x IOAB LP PPV + 2x IOAB
3 64 AC wash + IOAB LP Vitreous biopsy + 5x I
4 62 Vitreous biosy + IOAB 6/36 PPV + 2x IOAB
5 55 2x IOAB 6/36 PPV + IOAB + 2x Intrav
Amphoterecin B
IOAB intraocular (antibacterial) antibiotic injectionthe in-house endophthalmitis data [13, 14]. In our re-
port [14], culture-positive endophthalmitis was 0.07%;
in this cohort 64.8% (n = 24/37) grew gram-positive
cocci (n = 16/37, 43.2% were Staphylococcus epidermidis)
and 24.3% (n = 9/37) grew gram-negative bacilli (n = 5/37,
13.5% were P. aeruginosa). In the other report, [13] clin-
ical endophthalmitis was 0.09%, but the microbial profile
was not part of this report.
Our hypothesis that the profiles of the two groups of en-
dophthalmitis, in-house and referred could be different,
was only partly true. There were differences in twoprior to referral (group B)
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biological spectrum. The delay in reporting time of the re-
ferred patients was likely because it depended on the
referring ophthalmologist. The detection of more gram-
positive cocci in the in-house cases and more gram-
negative bacilli in referred cases was indeed a surprise
(Table 2). The microbial spectrum of in-house endoph-
thalmitis was closer to the EVS [2] and ECRS [3] reports.
It is possible that only more fulminant cases that did not
respond to initial treatment, invariably caused by gram-
negative or similar virulent organisms, were referred to
our facility.
The antibiotic sensitivity profile was nearly similar to
our earlier report. Gram-positive bacilli had good sensi-
tivity to vancomycin in either group, similar to the EVS
report [2], and the gram-negative bacilli had poor sensi-
tivity to ceftazidime in either group, similar to our earl-
ier report [1]. All ceftazidime resistant gram-negative
bacilli in group A (in-house cases) were sensitive to imi-
penem. Additionally, 77.78% of resistant isolates from
referred cases were sensitive to amikacin. Imipenem
appears to be good choice in gram-negative organisms
resistant to ceftazidime and amikacin [15–17]. Amikacin
could still be an alternative choice, though we have
already reported emergence of gram-negative bacteria
resistant to both ceftazidime and amikacin [18]. Hence it
is prudent to always do a culture-sensitivity test for ap-
propriate management.
The limitations of this study included small number of
cases (50 in either group), small number of individual
isolates tested for sensitivity, and non-inclusion of PCR
as routine basis. The strength of the study is the use of
uniform management protocol in both groups. The
study clearly demonstrates that the post cataract surgery
infection pattern in India may not be significantly differ-
ent from the ones reported by the EVS and ESCRS re-
ports, though one must employ wiser discretion in
treating the in-house and referred patients in a referral
facility such as ours.Conclusions
The study confirms that the gram-positive bacteria are the
most common in post cataract surgery endophthalmitis in
both in house and referred cases, but the gram-negative
bacteria are more common in the referred cases in the
teaching tertiary eye care facility in India. P. aeruginosa is
the common gram-negative bacteria, and increasingly,
they are resistant to commonly used antibiotic, ceftazi-
dime. Hence, a microbiology and antibiotic sensitivity is
mandatory while the EVS-based empiric treatment of
post cataract surgery endophthalmitis treatment could
continue for the time being. It is necessary to weigh the
clinical response vis-a-vis the culture sensitivity to make afurther decision. This implies seeing the patient 3–4 days
after the initial treatment.
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